DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Morgan Stanley Maintains Underweight on Biogen, Lowers Price Target to $261

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and lowers the price target from $270 to $261.

Benzinga · 01/31/2020 15:48

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and lowers the price target from $270 to $261.